Skip to main content
. Author manuscript; available in PMC: 2018 Mar 31.
Published in final edited form as: Circ Res. 2016 Dec 28;120(7):1139–1150. doi: 10.1161/CIRCRESAHA.116.309819

Figure 5. Endpoint: LVEF (%) in AMI swine studies. Grouped by route of cell delivery. Result: Favors TESI, DI, and IV.

Figure 5

Mean effect ± standard deviation (SD) of mesenchymal stem cells (Treatment) or placebo/no treatment (Control) on the improvement of LVEF (%) based on the route of delivery: intramyocardial injection (DI), transendocardial stem cell injection (TESI), intracoronary infusion (IC), and intravenous infusion (IV), in acute myocardial infarction (AMI) swine studies illustrating that TESI, DI, and IV favors MSC treatment while IC does not. Number of animals in each arm of the study (Total). Relative weight of each study (Weight). Mean difference between Treatment and Control with a 95% confidence interval (95% CI), using inverse variance (IV) and random effects model (Random).